Can I take prescribed medical cannabis from the UK to Japan?

Quick answer.

That means the answer depends on the formulation. Prescribed flower or resin should not be brought into Japan. A finished medicinal product such as an oil or capsule may fall under a different controlled-drug classification, but a UK prescription alone is not enough: the traveller should obtain written classification and, where applicable, advance permission from the Narcotics Control Department before departure.

UK → Japan checklist.

1. Identify the exact product, formulation and active ingredients. Japan classifies controlled substances by ingredient rather than by a UK brand or clinic name. Ask your prescriber or pharmacy for the generic ingredients, strength and daily dose.
2. If your medicine is cannabis flower or resin, do not pack it. Current MHLW personal-import guidance lists cannabis plant material and cannabis resin as prohibited imports.
3. For oils, capsules or other finished products, contact the Narcotics Control Department before travel. Ask the NCD office responsible for your Japanese arrival airport to confirm how the exact product is classified and whether personal traveller import is permitted.
4. If the product is treated as a narcotic, obtain advance permission. NCD guidance says travellers carrying narcotic medicines for their own treatment need permission before entering or leaving Japan.
5. Apply early. The NCD says applications should be submitted at least 14 days before travel. Last-minute handling is not guaranteed.
6. Prepare the medical certificate properly. The NCD requires the traveller's name and address, the specific medical reason for treatment, the medicine name, dose and strength, the prescriber's signature and an issue date within three months. It also asks for package photographs or equivalent product information.
7. If you will leave Japan with medicine remaining, check the export step too. NCD guidance says an export application may also be required for the return journey.
8. Carry the medicine yourself and present the certificate at Customs. A permitted controlled medicine cannot simply be posted to Japan or carried by somebody else on your behalf.
9. Check every transit country separately. Japanese permission does not authorise possession during a connection elsewhere.

What about prescribed cannabis oil?

Do not assume an oil is treated the same way as cannabis flower. Japan's revised framework uses ingredient and Δ9-THC thresholds to determine whether some products are narcotics. A finished oil containing controlled levels of Δ9-THC may therefore require the narcotics traveller-permission route rather than being treated as an ordinary prescription medicine.

The important point is not to classify the product yourself. Send the exact ingredient and strength information to the relevant NCD office and obtain written confirmation before travelling.

What about CBD products?

CBD-labelled products are a separate edge case. Japan introduced residual Δ9-THC limits for products, and a product above the relevant limit is treated as a narcotic. The NCD also offers a pre-import classification check for CBD- and CBG-related products where it is unclear whether the product falls within narcotics controls.

A UK label saying “CBD” therefore does not by itself establish that the product can be brought into Japan. Confirm the exact cannabinoid composition and Japanese classification before departure.

Can I use my UK prescription to obtain medical cannabis in Japan?

No — not as a simple refill. Japan's 2023 cannabis-law reform removed the old blanket barrier that prevented approved cannabis-derived medicines from being used, but it created a pharmaceutical approval route rather than a UK-style medical-cannabis flower market.

Access in Japan depends on whether a specific medicine is authorised for use there and on treatment through the Japanese medical system. A UK CBPM prescription is not a Japanese prescription and does not create an automatic pharmacy dispensing route.

How developed is Japan's cannabis-medicine pathway?

The position remains product-specific and developing. In June 2026, MHLW listed cannabidiol for Dravet syndrome, Lennox-Gastaut syndrome and tuberous sclerosis complex under Japan's orphan-drug designation framework. An orphan designation supports development and regulatory review; it is not the same thing as general marketing approval or a visitor refill service.

For a UK patient, the practical implication is to plan continuity before travel rather than expecting the same cannabis product, formulation or prescribing model to be available after arrival.

What should I do if I need treatment while in Japan?

If treatment continuity is essential, speak to your UK prescriber before departure about a lawful travel plan and any clinically appropriate alternatives. If you need treatment in Japan, you would need to use a Japanese medical provider and whatever medicines are lawfully available within the Japanese system.

Do not arrange for a clinic, friend or family member to post replacement controlled medicine to you. NCD guidance requires a traveller using the controlled-medicine permission route to carry the medicine personally.

Before departure.

Japan's rules are unusually formulation-specific, so recheck the NCD and MHLW guidance shortly before travel. For medical cannabis, written confirmation for the exact product is more useful than relying on general travel advice. Keep your prescription evidence, medical certificate, original labelled packaging and any Japanese import/export certificates readily accessible.

Prepare your travel evidence →